Maria Obrycka
Adult Health · New York, NYNPI 1033514013
Payments from drug & device makers
Across 204 payments — averaging $38.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Johnson & Johnson$785
- Novartis$748
- Pfizer$637
- Amgen$225
- plus $811 from 9 others
What the payments were for
- Food & beverage$7,816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $2,493 |
| AstraZeneca | 41 | $2,118 |
| Johnson & Johnson | 14 | $785 |
| Novartis | 39 | $748 |
| Pfizer | 28 | $637 |
| Amgen | 11 | $225 |
| Dexcom, Inc. | 1 | $170 |
| Boehringer Ingelheim | 2 | $160 |
| E.r. Squibb & Sons, L.L.C. | 7 | $159 |
| Lilly USA, LLC | 1 | $107 |
| Abbott | 4 | $105 |
| Kestra Medical Technology Services, Inc. | 1 | $40 |
| Bayer | 1 | $27 |
| Merck | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,816 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 65 | $87,576 |
| OzempicSemaglutide | 49 | $83,981 |
| EliquisApixaban | 49 | $42,510 |
| RybelsusSemaglutide | 12 | $23,683 |
| MounjaroTirzepatide | 24 | $23,051 |
| FarxigaDapagliflozin Propanediol | 13 | $18,037 |
| BrilintaTicagrelor | 16 | $13,028 |
| Testosterone | 21 | $2,747 |
| Levothyroxine Sodium | 52 | $1,890 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,349 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $1,164 |
| SynthroidLevothyroxine Sodium | 12 | $1,123 |
| Colchicine | 24 | $844 |
| ClopidogrelClopidogrel Bisulfate | 65 | $735 |
| Atorvastatin Calcium | 48 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,493 | $107,66461 claims |
| Boehringer IngelheimJardiance | $160 | $87,57665 claims |
| PfizerEliquis | $637 | $42,51049 claims |
| AstraZenecaFarxiga, Brilinta | $2,118 | $31,06529 claims |
| Lilly USA, LLCMounjaro | $107 | $23,05124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Alyson HartyNew York$65K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Jenna WenzelNew York$22K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.